D-Streptamine, O-6-amino-6-deoxy-α-D-glucopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-3-amino-2-hydroxy-1-oxopropyl]-2-deoxy-, sulfate (1:?)

The main ingredient of this product is isopamicin sulfate

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used in combination with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4. This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs, or used sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6. This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7. This product can often achieve synergistic effects when combined with beta-lactams (cephalosporins or penicillins). 8. This product can be mixed with beta-lactams (cephalosporins or penicillins) to cause mutual inactivation. When used in combination, it must be dripped in separate bottles.

The main ingredient of this product is isopamicin sulfate

1. This product combined with other aminoglycosides or applied topically or systemically successively can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. Hearing loss may occur, and may progress to deafness after drug discontinuation; hearing loss may recover or be permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). Anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product combined with neuromuscular blocking drugs can aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). Combined with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or successively applied topically or systemically

The main ingredient of this product is isopamicin sulfate

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used in combination with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4. This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs, or used sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6. This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7. This product can often achieve synergistic effects when combined with beta-lactams (cephalosporins or penicillins). 8. This product can be mixed with beta-lactams (cephalosporins or penicillins) to cause mutual inactivation. When used in combination, it must be dripped in separate bottles.